
price data provid thomson reuter
number may add due round
initi outperform growth ultomiri
initi outperform rate price target
recent approv launch ultomiri mark
new chapter compani stori histori team attempt begin
convers process away flagship therapi soliri overal see share
offer attract valuat ultomiri launch unfold addit
growth opportun still come complement grow pipelin effort
like setup total revenu estim slightli ahead
guid rang current consensu threat competit ever
present soliri execut thu far strong recent month
ultomiri rais competit bar believ oper
posit strength
launch ultomiri pnh patient us one quarter ago howev
convers patient soliri solid start patient
alreadi ultomiri recal manag guid convers
within two year post-launch roughli one year market soliri
gener myasthenia gravi gmg alreadi initi
patient manag guid largest opportun
soliri patient volum basi addit label expans still come
ahu ultomiri nmosd soliri see multipl growth lever ahead
compani
pipelin evolut get start creat option admittedli
relianc soliri remain high drug account
compani report product revenu end move toward
revenu sourc ultomiri posit move complement
ultomiri opportun manag focus expand
redefin pipelin sinc arriv current ceo ludwig hantson earli
present pipelin featur differ program mani
addit aim new target think pipelin help diversifi
revenu base time
still lot activ near-term think share continu work
commerci execut drive much stori remaind
howev still multipl regulatori catalyst potenti
approv soliri nmosd us pdufa region
japan eu cours look clariti pipelin
program readout subq ultomiri program
potenti phase data bottom line pair commerci execut
activ pipelin initi coverag outperform
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
alexion pharmaceut inc commercial-stag biopharmaceut compani focus develop
novel therapi rare diseas compani flagship product soliri eculizumab market
sinc approv treatment three differ therapeut indic includ paroxysm
nocturn hemoglobinuria pnh atyp hemolyt urem syndrom ahu gener myasthenia gravi
gmg beyond soliri market product portfolio encompass three addit drug recent
gain approv late call ultomiri ravulizumab-cwvz midst pipelin expans
current effort includ differ program span rang autoimmun rare diseas see
ultomiri launch enabl strong revenue/ep growth profil pipelin larg remain unmodel
stage risk/reward appear favor
major pre-exist soliri
patient convert ultomiri
pnh assum approv
ahu gmg follow
program delay fail
pipelin candid appli
progress prior biosimilar/
soliri sbla nmosd indic
potenti approv iv ultomiri ahu
target deriv multipl
ep discount back premium vs large-
cap consensu ep due orphan
product portfolio pipelin
inc headquart
boston center excel locat new
ct flagship product soliri approv
three differ indic pnh ahu gmg
soliris/ultomiri compris major
revenu base repres primari valu driver
investor sentiment compani roll
ultomiri pnh note use limit sampl
creat bluematrix
tabl content
fka wilson diseas
real biosimilar threat
valuat deep dive top bottom
zero biotech sector valuat
tabl figur
overview valuat
valuat analysi gmg
time cours ncc concentr three therapi
overview complement cascad dynam
select complement-medi therapeut develop
summari initi coverag outperform rate
price target ultomiri approv open door move beyond soliri
increas competit bar complement therapi develop addit
manag activ seek realign pipelin increas number late-stag
program distinct soliris/ultomiri like setup element thesi follow
overal view core large-cap hold orphan disease/neurolog space
onward ultomiri
soliri put map ultomiri mark import transit point
compani help move toward diversifi undertak launch pnh appear
proceed target toward manag goal convers second
approv ahu like arriv less year thwart biosimilar competit appear
feasibl view combin soliris/ultomiri revenu estim
ahead compani guidanc current consensu think
convers continu strong rate remaind year ahu
approv like provid momentum
grow neurolog franchis pipelin boost
april soliri gmg launch surpass patient treatment make
success launch histori potenti approv soliri nmosd
set pdufa june see nmosd opportun anoth growth lever
time estim global soliris/nmosd opportun contribut increment
revenu moreov addit pipelin opportun advanc
includ ultomiri like setup longer term area
complement complement pipelin evolut get start
sinc investor seen pipelin undergo transform realign
view put compani strong foundat import ultomiri
remain central invest addit novel agent
help facilit diversif effort decreas alxn relianc soliri
incorpor wilson diseas current estim leav numer upsid
opportun current valuat impli upsid share
current trade ultomiri convers pnh ahu fail manifest substanti
degre complet elimin eu revenu begin see downsid risk
level risk/reward appear favor numer regulatory/commerci updat
ahead pipelin larg uncaptur estim like setup share
initi outperform rate target
figur illustr alxn current product pipelin portfolio market agent
two promin agent soliri ultomiri former market sinc
approv three indic includ paroxysm nocturn hemoglobinuria
pnh atyp hemolyt urem syndrom ahu gener myasthenia gravi gmg
ultomiri gain approv treatment adult pnh decemb
beyond soliri ultomiri compani hold market product strensiq
kanuma sinc compani taken effort expand pipelin breadth depth
figur illustr pipelin three differ time point februari april
april length blue bar indic program statu gray/dot box
indic program develop specifi period
recal current ceo ludwig hantson appoint ceo role march initi
snapshot resembl state pipelin immedi prior entri
compani time number market products/ind increas four
six ultomiri pnh repres recent approv program also
review soliri nmosd ultomiri treatment ahu
although pipelin seen remov certain program
introduct new asset tie focu rare neurolog metabol disord
creat net growth total campaign evalu clinic set
discuss detail herein believ realign pipelin provid
better opportun support broader diversif away soliri
tabl summar upcom catalyst mileston relat compani
overal note near-term catalyst tie regulatori commerci mileston
key pipelin data event fall closer toward
describ detail herein deriv price target share use
compar multipl approach appli multipl non-gaap ep estim
discount back per year given compani stage develop earn
histori feel appropri approach compani pleas see pp
comprehens descript
overview valuat
best known effort soliri complement inhibit compani
also featur distinct pipelin focus metabol disord encompass market
product strensiq kanuma also develop agent develop
fka fka present develop pipelin
late announc acquisit syntimmun brought asset formerli
known human monoclon antibodi target neonat fc receptor
fcrn figur shown illustr interact fcrn immunoglobulin
igg normal condit within lysosom fcrn bind igg molecul rescu
degrad return igg molecul endosom fcrn dissoci igg
releas igg back bloodstream
howev mani autoimmun disord igg mediat diseas state prolong half-
life contribut pathogen state thu one therapeut strategi disrupt
fcrn/igg interact formerli bind fcrn
prevent degrad rescu igg thought level igg declin improv
diseas state
figur shown illustr result phase studi patient
dose addit standard care corticosteroids/immunosuppress shown
subject experienc reduct total igg level day cours
treatment addit level circul immun complex cic also drop similar
degre notabl declin occur sub-therapeut dose
studi enrol small patient number safety/toler profil overal appear
manag grade result report dose interrupt discontinu
reduct although two seriou advers event sae report deem
unrel drug given background therapi diseas state see profil strong
stage
may appli mani place includ mg continuum
one condit may benefit anti-fcrn gener myasthenia gravi gmg due
role igg express extern preclin data provid valid target
appear mediat gmg data report smith colleagu ucb
demonstr iv dose monkey reduc plasma igg level day
sustain revers declin shown week safeti profil appear
soliri alreadi approv refractori gmg patient ultomiri evalu
pivot studi remain larg proport gmg univers address
either therapi figur illustr envis dynam chang
introduct possibl anti-fcrn agent ultomiri soliri
like best posit downstream toward refractory/sever patient someth like
may offer benefit earlier-stag diseas sever popul compris
patient leav address opportun order patient
present formal incorpor program estim howev
follow analysi illustr back-of-the-envelop estim program
could deliv term upsid valu focus sole gmg opportun assum
address popul patient net global price point per patient
estim market penetr probability-adjust basi increas valuat
see figur increas probability-of-success result
valuat analysi gmg
analysi also incorpor success indic warm antibodi
hemolyt anemia waiha pemphigu vulgari pv applic also like
competitor examin condit itp cidp bottom line appear
establish proof-of-concept fcrn mechan await data
inform may best suit
fka wilson diseas
given current develop path earliest potenti market entri
agent like time frame outsid ultomiri develop effort
formerli known decupr repres anoth agent advanc
project market entri recal obtain acquisit
wilson origin develop univers michigan
advanc attenuon llc/tactic acquisit wilson therapeut
molecul bis-cholin tetrathiomolybd salt tetrathiomolybd cholin
believ capabl form stabli complex copper protein
albumin excret via bile
wilson diseas repres genet disord patient accumul copper within
bodi liver manifest wilson diseas typic condit first recogn
literatur suggest wilson diseas occur rare frequenc thought featur
incid per nih estim approxim us patient
similar level region excess level copper caus direct oxid stress well
induct beyond liver implic cirrhosi symptom includ
neurolog manifest parkinson like tremor ataxia psychiatric/behavior
chang diagnosi accomplish evalu serum urin copper level well
kayser-fleisch ring eye
therapeut option limit wilson diseas patient standard-of-car involv
treatment chelat agent bind copper ion remov bodi
front-lin treatment cuprimin d-penicillamin use chelat agent bind
metal spyrin trientin anoth agent approv wilson diseas patient
intoler penicillin therapi penicillamin therapi without limit wilson
diseas associ note potenti toxic associ treatment moreov mani
treatment must taken multipl time per day make adherence/compli
complic factor last onset efficaci often take weeks/month exist
therapi thu stand demonstr improv multipl measur
date evalu patient wilson diseas oncolog
set review clinic data weiss colleagu previous report
result open-label phase studi wilson diseas studi recruit
patient leipzig score establish diagnosi wilson diseas non-
ceruloplasmin-bound copper level ncc lower limit normal refer rang
ceruloplasmin protein blood typic bind copper primari
endpoint studi evalu chang ncc level baselin week
figur shown illustr chang ncccorrect measur week
reduct manifest within first month mean valu drop baselin
week subject met criteria treatment success
defin achievement/mainten normal ncccorrect level
upper limit normal reduct ncccorrect
compar exist therapi safety/toler basi think data
compar favor discontinu rate approv therapi vari retrospect
suggest level rang patient discontinu depend regimen
instanc high neurolog manifest also
contribut poor adher within phase studi subject complet studi
subject discontinu due drug-rel advers event three subject discontinu
due alt elev found revers concomit increas
bilirubin level case neurolog worsen report first week
studi treatment-nav patient
term efficaci attempt put result context versu phase
studi use open-label design activ compar unclear ncc valu
pfeiffenberg correct least provid gaug magnitud benefit focus
six-month time point relev observ reduct
appear greater dpa d-penicillamin
time cours ncc concentr three therapi
key question becom durabl efficaci long
maintain long-term extens data phase studi demonstr ncc level
maintain week mean ncc valu
figur illustr focu studi design studi origin design
evalu non-inferior amend studi
complet acquisit wilson therapeut interim analysi perform
sampl size re-estim anticip provid visibl efficaci
data could potenti lead increas studi size variabl copper
measur greater normal
studi enrol two cohort nave treatment second group
receiv standard care soc one month trial power demonstr
superior primari endpoint chang non-ceruloplasmin-bound copper level
baselin week
put togeth wilson diseas opportun may larg soliri
ultomiri see import tool provid product revenu diversif
addit look expand metabol franchis footprint would appear
agent allow compani leverag exist infrastructur
complement cascad play import role adapt innat immun
central compon immun system abnorm signal lead pathogen
condit figur illustr balanc must
overview complement cascad dynam
creat bit double-edg sword drug develop perspect one
hand modul complement signal potenti posit impact certain diseas state
howev mani exampl fail complement inhibitor includ
yield success therapeut agent backdrop note continu
numer compani engag develop novel complement inhibitor therapeut
figur summar on-going effort space accord
advanc develop stage well diseas mechan note sever key takeaway
tabl first complement inhibit sought-aft therapeut strategi
evidenc broad rang compani pursu effort may landscap
assess encompass drug major activ develop
select complement-medi therapeut develop
note number locat outsid circl either discontinu develop statu uncertain
adapt harri ricklin et al clinicaltri gov compani report wedbush secur inc research
second point challeng space find success although soliri
market sinc even setback develop complement-
target therapi figur incorpor program either longer
develop uncertain statu demonstr point
final note sever soliri biosimilar campaign also develop abp
recent one biosimilar molecul approv sale russia selexi howev
manag commentari indic unlik gain approv ex-u
region due need clinic studi conduct specif geographi soliri
repres larg revenu opportun walk detail wonder
true magnitud biosimilar opportun part due number player
also due introduct ultomiri
real biosimilar threat
biosimilar often cite potenti tool reduc cost system compar brand
greater valuat compar biosimilar candid larger-scal product remicad
humira howev review current biosimilar landscap us europ
think analys limit might reflect dynam marketplac
moreov orphan biosimilar uniqu challeng discuss
challeng like impact biosimilar competit
price impact lever us biosimilar agent launch
filgrastim biosimilar repres exampl price fail drive
may reflect discounting/reb us also initi
discount brand list price limit incent migrat patient
brand product biosimilar soliri price point consider higher
rebating/discount come play may greater room discount
price drive adopt howev ultomiri price creat addit challeng
initi load dose pnh ultomiri price premium soliri note
ultomiri price discount rel soliri pnh indic ahu
subsequ years/mainten treatment thu biosimilar entrant would like
price discount ultomiri use uptak lever
patient identif funnel constrain newer entrant pnh ahu repres disord
occur low incid rate even preval popul repres
sever thousand patient within given geographi mani physician even awar
disease/diagnosi compani must master patient identif
logist end see tradit biosimilar compani lack infrastructur
robustli identifi new patient least disadvantag compar player like
phase studi dahlia compar biosimilar agent abp versu soliri adult
pnh subject see studi incorpor crossov design
span year trial anticip complet per clinicaltri gov
manag guid convert us pnh market within two year
post-launch would coincid time frame thu biosimilar
unlik reach market appear suffici time migrat
market toward ultomiri
physician/pati trust brand agent payer like exert sizabl influenc
whether switch mandat want trivial import thing like
brand loyalti suppli chain logist may come play particularli condit
life-threaten complic contrast diseas rheumatoid
arthriti consequ fail therapi may differ
clear want overlook biosimilar threat relat soliri must
maintain strong push toward migrat patient ultomiri said think
hold good posit time perspect select price point would seem
limit price biosimilar adopt driver
better illustr dynam orphan-focus biosimilar figur walk
hypothet math orphan biosimilar product broader indic
rheumatoid arthriti multipl sclerosi etc off-set price discount increas volum
adopt necessarili case orphan condit fewer pnh
patient estim us current estim assum avail treat
ultomiri price discount soliri repres greater discount
indic ahu biosimilar like need price
substanti discount realiz adopt two scenario shown assum one case
biosimilar price discount soliri second scenario price
discount manag guid convers ultomiri assum
biosimilar could reach market share although hypothet figur put
togeth math would seem challeng realiz meaning econom
limit number patient increas volum compens price discount
orphan set like chronic diseas
us pnh patientsannu soliri biosimilar scenariosmarket avail pariti ultomiri vs soliri total revenu cost assum revenu cost assum revenu cost assum revenu discount soliri ultomiristot revenu cost assum revenu cost assum revenu cost assum revenu
describ detail current market model alxn market product
complement metabol space numer pipelin effort underway
much remain call option await proof-of-concept data assign full
credit model overal model complement inhibitor soliri ultomiri total
franchis estim rather product-specif basi anticip convert
major user base toward ultomiri across cours within us
similar dynam unfold europ approv arriv
start pnh ahu
overal view pnh ahu segment provid foundat base soliri
ultomiri manag disclos revenu indic estim soliri
gener combin pnh/ahu revenu introduct ultomiri
estim franchis continu grow pnh/ahu revenu annual part
market expans increas avail number elig patient treat
move mg
mg launch complet first full year market penetr pick steam
estim gmg patient treatment manag anticip
indic largest one term patient volum
wedbush secur inc estim compani report
current market product within metabol franchis includ strensiq
kanuma figur illustr respect market model product overal
anticip modest growth kanuma go forward revenu reach
strensiq anticip continu steadi double-digit revenu growth
product revenu reach growth remain lever toward patient
identif ex-u geographi like provid biggest opportun
 soliris/ultomirisestim mg estim patient achr market avail soliris/ultomiri mgestim soliris/ultomiri mg market share patients- per patient per annual price mg us revenu
wedbush secur inc estim compani report
wedbush secur inc estim compani report
leav major pipelin call option stage incorpor credit
fka wilson diseas set larg base current
phase data set on-going pivot studi enrol review
assumpt data anticip assum earliest potenti commerci launch
would commenc
shown figur assum predomin sourc valu deriv patient
us two region compris patient present
estim roughli half market diagnos activ seek treatment assum
demonstr superior profil versu standard-of-car help drive
patient toward treatment addit assum entranc once-daili oral
agent improv safety/toler profil help expand overal address
market size via patient remain therapi model modest contribut
apac row market estim ww revenu reach
wedbush secur inc estim compani report
term price assum pivot studi demonstr superior
versu exist treatment although gener spyrin agent avail price remain high
exce per year per patient remain conserv estim price
gross basi discount exist therapi discount reduc
roughli per patient per quarter per patient per year net basi
valuat deep dive top bottom
zero biotech sector valuat
tabl summar current valuat metric large-cap mid-cap commerci
stage biotechnolog compani among large-cap note group current trade
mean price-to-earnings rel consensu ep estim p/ metric group trade
mean multipl consensu revenu mid-cap group metric diverg slightli
revenu see relev peer group large-cap group
note price
compar histor basi figur attempt put tempor context
around current sector-level valuat histor sinc large-cap peer group
rel histor premium howev note sinc
large-cap biotech peer group start trade discount broader market
look ahead near term see ultomiri commerci adopt addit ultomiri
pipelin updat soliri ip updat key driver share previous state
deriv price target share use earn multipl approach primari
valuat methodolog believ repres appropri approach
matur commercial-stag biotech like particularli compani establish
histori earn
assumpt incorpor base case analysi includ discount rate
standard rate appli commercial-stag compani regard specif
program incorpor assign full credit exist product portfolio
revenu extend period defin regulatori exclus instanc
addit issu patent extend runway factor timelin
pipelin opportun incorpor credit leav remaind
pipelin upsid estim also assign credit nmosd opportun
soliri previous disclos data appear clinic compel compani file
snda indic pdufa project june current hold net
debt posit debt total cash equat roughli
price-to-earnings multipl approach repres primari valuat methodolog use deriv
price target also examin potenti valuat use altern method note
similar primari valuat approach altern methodolog also sensit
select discount rate multipl valuat year figur illustr fair
shown figur select valuat year p/ analysi
like steady-st period follow ultomiri convers adher
discount rate also consist rate use primari valuat methodolog see
mean peer revenu multipl rang consensu revenu select
revenu multipl in-lin large-cap peer group project annual revenu
growth appear fall mean large-cap group vs
shown figur deriv potenti fair valu use sum-of-part dcf
methodolog stay consist discount rate use methodolog
assign credit current market product soliris/ultomiri strensiq kanuma
well anticip nmo opportun soliri wilson diseas
deriv fair valu estim valuat appear lower
estim deriv use multipl approach leav addit pipelin opportun
current estim would serv potenti upsid lever
deriv base case price target share also examin potenti
bull bear case scenario better understand current upside/downsid movement rel
share current trade start bear case scenario envis worst-
case scenario may one soliri remov earli market due patent
challeng prior full convers ultomiri introduct ultomiri pnh
us mitig potenti eros risk us ultomiri patent exclus extend
complet elimin eu soliris/ultomiri franchis revenu begin
increas discount rate lower sum-of-part dcf fair valu estim
altern also examin potenti upsid current base case scenario
sever key lever may gener upsid first multipl expans one logic lever
current share trade discount large-cap peer group consensu
earn vs increas valuat multipl yield fair valu
second addit pipelin success anoth clear way could see upsid
estim mani effort late-stag studi hold multipl
possibl indic target option pipelin
figur illustr current risk/reward setup share rel
stock current trade think probabl success expans ultomiri label
strong given weve seen readout alreadi pnh ahu compani
alreadi gain strong user base gmg think challeng successor
demonstr meaning benefit patient switch
note price
alexion inc boston-bas commercial-stag biopharma focus discov develop
market novel therapi neurolog neurodegen condit origin
found leonard bell steven squinto initi effort focus
develop complement inhibitor ultra-rar diseas preliminari data soliri
eculizumab report earli compani becam publicli trade
flagship product soliri origin approv treatment pnh sinc
seen label expand encompass ahu gener mg
commentari highlight key element guidanc follow manag
report financi result note pre-exist consensu thomson reuter
revenu ep respect ahead guidanc
rang midpoint rang alxn guidanc call y/i revenu growth
overal alxn current manag team hold extens experi discoveri
develop market biopharma product member execut team
describ
dr hantson serv alexion ceo sinc prior appoint alexion dr
hantson serv ceo baxalta addit experi baxalta/baxt dr
hantson held seri senior role novarti johnson johnson dr hantson obtain
master degre ph univers louvain belgium
mr clanci join alexion team appoint compani chief
financi offic role mr clanci respons oversight financi manag
treasuri intern audit corpor strategi busi develop secur activ
investor relat mr clanci previous serv cfo addit experi
senior role mr clanci obtain babson colleg
mr goff appoint alexion chief commerci offic lead global
commerci oper prior addit alexion team mr goff held senior
commerci market role neurov novarti baxalta baxter johnson
johnson mr goff obtain skidmor colleg univers
john orloff evp head
dr orloff join alexion team appoint execut vice presid
compani head research develop dr orloff overse clinic research
program regulatory/med affair support busi develop effort prior
appoint alexion dr orloff head effort novelion baxalta addit
role baxter merck serono dr orloff receiv dartmouth colleg
univers vermont
atherfold dhoogh finney greenslad et al gener
character high affin anti-human fcrn antibodi rozanolixizumab
effect differ molecular format reduct plasma igg concentr
medici sturniolo tetrathiomolybd copper chelat treatment
wilson diseas pulmonari fibrosi indic idrug
rodriguez-castro hevia-urrutia sturniolo wilson diseas review
nichol flint olsson et al bis-cholin tetrathiomolybd patient
ferenc stremmel zinc monotherapi effect chelat agent
treatment wilson diseas gastroenterolog
 gauss long-term evalu urinari copper excret noncaeruloplasmin
associ copper wilson diseas patient medic treatment inherit
harri expand horizon complement drug discoveri challeng emerg
ricklin mastello lambri complement
gutierrez financi analysi biosimilar develop candid studi
us biosimilar busi
dowlat opportun challeng biosimilar orphan expert opin
uptak biolog filgrastim biosimilar product among medicar
incom statement good sold gross sg total oper oper profit invest interest incom total non-operating non- pre-tax incom incom tax effect tax rate net incom net net incom basic weight averag common dilut weight average common share dilut weight average common share basic ep dilut ep basic ep dilut ep
balanc sheet cash/cash assetscurr assetscash cash market trade account receiv prepaid expens current total current non-curr assetsproperti equip intang asset right use oper total non-curr total liabil sharehold equitycurr liabilitiesaccount revolv credit facility- accru defer current portion long-term current portion conting current total current non-curr liabilitieslong-term debt less current conting facil leas defer tax non-current oper leas non-curr total non-curr total sharehold equitypref stockcommon total sharehold
statement incom loss depreci impair intang chang fair-valu conting payment conting consideration- stock-bas non-cash expens acquir ipr d- defer incom unreal foreign currenc gain- unreal loss forward unreal gain equiti investments- net incom work capit adjustmentsaccount prepaid account payabl accru expens current defer revenue- chang assets- net work capit usag invest activitiespurchas market proce sale/matur market purchas mutual fund relat ndc proce sale mutual fund relat ndc purchas trade securiites- purchas purchas strateg payment acquir intang usag financ activitiesdebt issuanc costs- proce resolv credit facility- payment term repay line repurchas common proce issuanc stock share-bas payment conting payment facil leas obligation- usag effect exchang rate net chang begin end valuat
target deriv multipl ep discount back premium vs large-cap
consensu ep due orphan product portfolio pipelin
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
may
may
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
